Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically (histologically) proven diagnosis of non-muscle invasive (Ta, Tis or T1) bladder cancer~* In their treating physician's opinion is a good candidate for BCG therapy~* Be able to give informed consent~* Be age 18 or older~* Not be in an immunosuppressed state (e.g. HIV, use of chronic steroids)~* Not have active, uncontrolled infections~* Not be on agents known to alter rapamycin metabolism significantly~* Not have a reported history of liver disease (e.g. cirrhosis)~* Not have a prior history of non-bladder cancer unless the cancer is clinically stable and not requiring active treatment except basal cell carcinoma or squamous cell carcinoma of the skin.~* Not pregnant, or taking effective contraception before rapamycin therapy, during therapy and for 12 weeks after discontinuation of therapy.~Exclusion Criteria:~* Have muscle-invasive (≥T2) bladder cancer~* Unable to give informed consent~* Age \< 18~* Immunosuppressed state (e.g. HIV, use of chronic steroids)~* Active, uncontrolled infections~* On agents known to alter rapamycin metabolism significantly~* Another cancer requiring active treatment (except basal cell carcinoma or squamous cell carcinoma of the skin)~* Patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for 12 weeks after discontinuation of therapy.~* Individuals with a reported history of liver disease (e.g. cirrhosis)~* Individuals who are not a good candidate for BCG in their treating physician's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rapamycin 0.5mg (Type: ACTIVE_COMPARATOR): Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
- Rapamycin 2.0mg (Type: ACTIVE_COMPARATOR): Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
- Control (Type: NO_INTERVENTION): Subject will be apart of the control group and won't take the study drug being tested

Based on this trial design, predict the completion outcome and termination type (if applicable).